Stereotaxis Announces Positive Results from First 50 Clinical Procedures Performed with New Niobe ES™ System

Stereotaxis, Inc.

today announced the completion of the first 50 clinical procedures using the Company's new Niobe ES™ system to treat patients with a variety of complex cardiac arrhythmias. A majority of the first 50 cases were performed to treat atrial fibrillation, the most common type of cardiac arrhythmia(1). Positive initial results with the Niobe ES system in Europe demonstrate that the average time for completion of mapping and ablation for the initial AF patients was 69 minutes. The data will be featured at the Boston Atrial Fibrillation Symposium 2012 to be held on January 12-14, 2012. The Epoch™ platform, which encompasses the Niobe ES system, is the Company's new generation comprehensive solution for the electrophysiology laboratory. It is designed to improve efficiency with a fully-remote, networked and modular robotic, magnetic system that enables greater surgical precision and improved catheter control while reducing the risk of complications. Stereotaxis began initial shipments of the Epoch platform in mid-December 2011, including six system upgrades from the Niobe® II navigation system at leading medical centers in the United States and Europe.